Cargando…

Non-active site mutants of HIV-1 protease influence resistance and sensitisation towards protease inhibitors

BACKGROUND: HIV-1 can develop resistance to antiretroviral drugs, mainly through mutations within the target regions of the drugs. In HIV-1 protease, a majority of resistance-associated mutations that develop in response to therapy with protease inhibitors are found in the protease’s active site tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Bastys, Tomas, Gapsys, Vytautas, Walter, Hauke, Heger, Eva, Doncheva, Nadezhda T., Kaiser, Rolf, de Groot, Bert L., Kalinina, Olga V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236880/
https://www.ncbi.nlm.nih.gov/pubmed/32430025
http://dx.doi.org/10.1186/s12977-020-00520-6
_version_ 1783536227173007360
author Bastys, Tomas
Gapsys, Vytautas
Walter, Hauke
Heger, Eva
Doncheva, Nadezhda T.
Kaiser, Rolf
de Groot, Bert L.
Kalinina, Olga V.
author_facet Bastys, Tomas
Gapsys, Vytautas
Walter, Hauke
Heger, Eva
Doncheva, Nadezhda T.
Kaiser, Rolf
de Groot, Bert L.
Kalinina, Olga V.
author_sort Bastys, Tomas
collection PubMed
description BACKGROUND: HIV-1 can develop resistance to antiretroviral drugs, mainly through mutations within the target regions of the drugs. In HIV-1 protease, a majority of resistance-associated mutations that develop in response to therapy with protease inhibitors are found in the protease’s active site that serves also as a binding pocket for the protease inhibitors, thus directly impacting the protease-inhibitor interactions. Some resistance-associated mutations, however, are found in more distant regions, and the exact mechanisms how these mutations affect protease-inhibitor interactions are unclear. Furthermore, some of these mutations, e.g. N88S and L76V, do not only induce resistance to the currently administered drugs, but contrarily induce sensitivity towards other drugs. In this study, mutations N88S and L76V, along with three other resistance-associated mutations, M46I, I50L, and I84V, are analysed by means of molecular dynamics simulations to investigate their role in complexes of the protease with different inhibitors and in different background sequence contexts. RESULTS: Using these simulations for alchemical calculations to estimate the effects of mutations M46I, I50L, I84V, N88S, and L76V on binding free energies shows they are in general in line with the mutations’ effect on [Formula: see text] values. For the primary mutation L76V, however, the presence of a background mutation M46I in our analysis influences whether the unfavourable effect of L76V on inhibitor binding is sufficient to outweigh the accompanying reduction in catalytic activity of the protease. Finally, we show that L76V and N88S changes the hydrogen bond stability of these residues with residues D30/K45 and D30/T31/T74, respectively. CONCLUSIONS: We demonstrate that estimating the effect of both binding pocket and distant mutations on inhibitor binding free energy using alchemical calculations can reproduce their effect on the experimentally measured [Formula: see text] values. We show that distant site mutations L76V and N88S affect the hydrogen bond network in the protease’s active site, which offers an explanation for the indirect effect of these mutations on inhibitor binding. This work thus provides valuable insights on interplay between primary and background mutations and mechanisms how they affect inhibitor binding.
format Online
Article
Text
id pubmed-7236880
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72368802020-05-27 Non-active site mutants of HIV-1 protease influence resistance and sensitisation towards protease inhibitors Bastys, Tomas Gapsys, Vytautas Walter, Hauke Heger, Eva Doncheva, Nadezhda T. Kaiser, Rolf de Groot, Bert L. Kalinina, Olga V. Retrovirology Research BACKGROUND: HIV-1 can develop resistance to antiretroviral drugs, mainly through mutations within the target regions of the drugs. In HIV-1 protease, a majority of resistance-associated mutations that develop in response to therapy with protease inhibitors are found in the protease’s active site that serves also as a binding pocket for the protease inhibitors, thus directly impacting the protease-inhibitor interactions. Some resistance-associated mutations, however, are found in more distant regions, and the exact mechanisms how these mutations affect protease-inhibitor interactions are unclear. Furthermore, some of these mutations, e.g. N88S and L76V, do not only induce resistance to the currently administered drugs, but contrarily induce sensitivity towards other drugs. In this study, mutations N88S and L76V, along with three other resistance-associated mutations, M46I, I50L, and I84V, are analysed by means of molecular dynamics simulations to investigate their role in complexes of the protease with different inhibitors and in different background sequence contexts. RESULTS: Using these simulations for alchemical calculations to estimate the effects of mutations M46I, I50L, I84V, N88S, and L76V on binding free energies shows they are in general in line with the mutations’ effect on [Formula: see text] values. For the primary mutation L76V, however, the presence of a background mutation M46I in our analysis influences whether the unfavourable effect of L76V on inhibitor binding is sufficient to outweigh the accompanying reduction in catalytic activity of the protease. Finally, we show that L76V and N88S changes the hydrogen bond stability of these residues with residues D30/K45 and D30/T31/T74, respectively. CONCLUSIONS: We demonstrate that estimating the effect of both binding pocket and distant mutations on inhibitor binding free energy using alchemical calculations can reproduce their effect on the experimentally measured [Formula: see text] values. We show that distant site mutations L76V and N88S affect the hydrogen bond network in the protease’s active site, which offers an explanation for the indirect effect of these mutations on inhibitor binding. This work thus provides valuable insights on interplay between primary and background mutations and mechanisms how they affect inhibitor binding. BioMed Central 2020-05-19 /pmc/articles/PMC7236880/ /pubmed/32430025 http://dx.doi.org/10.1186/s12977-020-00520-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bastys, Tomas
Gapsys, Vytautas
Walter, Hauke
Heger, Eva
Doncheva, Nadezhda T.
Kaiser, Rolf
de Groot, Bert L.
Kalinina, Olga V.
Non-active site mutants of HIV-1 protease influence resistance and sensitisation towards protease inhibitors
title Non-active site mutants of HIV-1 protease influence resistance and sensitisation towards protease inhibitors
title_full Non-active site mutants of HIV-1 protease influence resistance and sensitisation towards protease inhibitors
title_fullStr Non-active site mutants of HIV-1 protease influence resistance and sensitisation towards protease inhibitors
title_full_unstemmed Non-active site mutants of HIV-1 protease influence resistance and sensitisation towards protease inhibitors
title_short Non-active site mutants of HIV-1 protease influence resistance and sensitisation towards protease inhibitors
title_sort non-active site mutants of hiv-1 protease influence resistance and sensitisation towards protease inhibitors
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236880/
https://www.ncbi.nlm.nih.gov/pubmed/32430025
http://dx.doi.org/10.1186/s12977-020-00520-6
work_keys_str_mv AT bastystomas nonactivesitemutantsofhiv1proteaseinfluenceresistanceandsensitisationtowardsproteaseinhibitors
AT gapsysvytautas nonactivesitemutantsofhiv1proteaseinfluenceresistanceandsensitisationtowardsproteaseinhibitors
AT walterhauke nonactivesitemutantsofhiv1proteaseinfluenceresistanceandsensitisationtowardsproteaseinhibitors
AT hegereva nonactivesitemutantsofhiv1proteaseinfluenceresistanceandsensitisationtowardsproteaseinhibitors
AT donchevanadezhdat nonactivesitemutantsofhiv1proteaseinfluenceresistanceandsensitisationtowardsproteaseinhibitors
AT kaiserrolf nonactivesitemutantsofhiv1proteaseinfluenceresistanceandsensitisationtowardsproteaseinhibitors
AT degrootbertl nonactivesitemutantsofhiv1proteaseinfluenceresistanceandsensitisationtowardsproteaseinhibitors
AT kalininaolgav nonactivesitemutantsofhiv1proteaseinfluenceresistanceandsensitisationtowardsproteaseinhibitors